Q-omics provides the consensus-scored GEM profile across patient tissues and cancer cell-line models. GEM expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GEM is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, GEM RNA expression shows 19,959 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, BLCA, and LSCC as cancer lineages where GEM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GEM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GEM survival associations across molecular data types. GEM RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GEM RNA expression–survival associations across cancer types. High GEM expression shows unfavorable associations in UVM, BLCA, THCA, LGG and COAD, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GEM RNA expression.
This table summarizes GEM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GEM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GEM shows lower tumor expression in BLCA, KICH, UCEC, BRCA, LUSC and PRAD. The BLCA box plot shows higher GEM RNA expression in normal versus tumor tissue (log2 FC = −3.394, t-test p < 0.001).
This table shows molecular features associated with GEM in patient tissues and cancer cell lines. In patient samples, GEM shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GEM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and CNS.
